Martin Heller, Clara Blanca Henrici, Judith Büttner, Sebastian Leube, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka Schanz, Agnes Hallier, Eva Herrmann, Michael Schmidt, Christoph Sarrazin
- Objectives In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed.
Methods: Patients in the intervention groups received bamlanivimab or casirivimab/imdevimab. Patients without treatment served as control. Outcomes were assessed by clinical symptoms and change in log viral load from baseline based on the cycle threshold over a period of 18 days.
Results: Median log viral load decline was higher in both intervention groups after 3 and 6 days compared to control. However, at later time points, the decline of the viral load was more distinct in the control group. Mild symptoms of COVID-19 were observed in 6.3% of the intervention groups and in no patient of the control. No patients treated with bamlanivimab, 18.8% treated with casirivimab/imdevimab, and 14.2% in the control group developed moderate symptoms. Severe symptoms were recorded only in the control group (14.2%), including one related death.
Conclusion: Treatment with monoclonal SARS-CoV-2 antibodies seems to accelerate decline of virus loads, especially in the first 6 days after administration, compared to control. This may be associated with a reduced likeliness of a severe course of COVID-19.
MetadatenAuthor: | Martin HellerGND, Clara Blanca HenriciGND, Judith Büttner, Sebastian LeubeGND, Isabelle Treske, Petra Pospischil, Michael Doll, Ilka SchanzGND, Agnes HallierGND, Eva HerrmannORCiDGND, Michael SchmidtORCiD, Christoph SarrazinGND |
---|
URN: | urn:nbn:de:hebis:30:3-788570 |
---|
DOI: | https://doi.org/10.1016/j.ijid.2023.01.012 |
---|
ISSN: | 1201-9712 |
---|
Parent Title (English): | International journal of infectious diseases |
---|
Publisher: | Elsevier |
---|
Place of publication: | Amsterdam |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2023/03/04 |
---|
Date of first Publication: | 2023/01/21 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2023/11/13 |
---|
Tag: | Antibody therapy; Bamlanivimab; COVID-19; Casirivimab; Imdevimab; Viral load |
---|
Volume: | 129 |
---|
Page Number: | 6 |
---|
First Page: | 260 |
---|
Last Page: | 265 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |
---|